Chloe Kent
Chloe is an award-winning journalist who has specialized in health reporting throughout her career, with a particular focus on women's health and access to medicine. Before joining Generics Bulletin she worked for B2B publishing consortium Verdict, writing about medical technology and pharmaceuticals. Having graduated from the University of York, she went on to train as a journalist with the Press Association.
Latest From Chloe Kent
ANI ‘On The Cusp Of A Transformation’ Following Cortrophin Launch
ANI Pharmaceuticals appeared confident about its Cortrophin gel launch and integration of Novitium Pharma as it rounded up its Q1 results, but net losses have dampened the company’s share value.
Inflation Impact Must Be Considered During Generics Pricing, Says Canadian Study
Canadian provinces must consider the impact of inflation on generic drugs during the next round of off-patent price setting, says a study from Aviseo and the Canadian Generic Pharmaceutical Association.
Revolving Door Of Executive Changes At Perrigo As Firm Revises Its Expectations Up
Perrigo is set to welcome a new chief financial officer and corporate security head as it rounds up a fairly successful first quarter.
Biosimilars Forum Calls For Further Action On Biden’s Competition Order
Generics Bulletin sits down with Biosimilars Forum executive director Julie Reed to discuss preparing the HHS for Humira biosimilars, what more the agency could do for the industry and the Forum’s priorities over the next year.
Formycon Highlights Greater Focus On Biosimilars As Athos Deal Completes
Formycon has completed its acquisition of Athos’ biosimilar candidates for Stelara and Lucentis, following the announcement of the deal in March.
Pfizer Anticipates ‘Fair’ Share Of Adalimumab Market In US
Pfizer expects to make significant strides in the adalimumab market once it launches its Humira biosimilar late next year, but may not be able to enjoy its anticipated interchangeability designation until 2024.